Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- Two Drugs that Hit One Target Improve Survival in Women with Metastatic Breast Cancer
(Updated: 10/01/2014) - Combining two drugs that target the HER2 protein, trastuzumab (Herceptin®) and pertuzumab, with chemotherapy is a new treatment option for women with HER2-positive metastatic breast cancer, according to final results from a large clinical trial.
- Enzalutamide Improves Survival in Patients with Metastatic Prostate Cancer
(Posted: 06/27/2014) - In an international randomized phase III clinical trial, the hormone therapy enzalutamide (Xtandi®) extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation therapy. Participants in the trial had not received chemotherapy.
- Ibrutinib Improves Survival Compared with Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia
(Posted: 06/27/2014) - In an international randomized phase III clinical trial, patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were treated with ibrutinib (Imbruvica®) lived longer without their disease getting worse than patients who received ofatumumab (Arzerra®). Patients who received ibrutinib also lived longer and were more likely to show a clinical response to treatment than those who received ofatumumab.
- New treatment option for young women with hormone-sensitive breast cancer
(Posted: 06/01/2014) - A drug used for treating breast cancer, known as exemestane, is more effective than a common breast cancer prevention drug, tamoxifen, in preventing breast cancer recurrence in young women who also receive post-surgical treatment to suppress ovarian function. The combined results of the Tamoxifen and Exemestane Trial and Suppression of Ovarian Function Trial were presented at the 2014 ASCO Annual Meeting in Chicago.
- NIH-funded study shows increased survival in men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy
(Posted: 12/05/2013, Updated: 06/01/2014) - Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early results from a NIH-supported randomized controlled clinical trial.